International Cancer Advocacy Network (ICAN) | Advocacy Groups

New treatments may stall lung cancer progression in patients with EGFR exon 20 insertion mutations.

A man with lung cancer shares how learning about his EGFR exon 20 insertion mutation soon after being diagnosed has allowed him to be aggressive when pursuing a cancer treatment tailored to his rare mutation.

Before closing out their discussion on treatment for EGFR Exon 20–Positive NSCLC, experts discuss prominent unmet needs in this setting.

A shared discussion on the importance of enrolling in clinical trials for EGFR exon 20–positive NSCLC and improving access to novel therapy for patients.

A focused conversation on how a patient can maintain and improve quality of life while receiving therapy for non–small cell lung cancer.

Comprehensive discussion on support for patients receiving therapy for NSCLC, ranging from care team members to education materials to support groups.

Looking at available novel therapy for EGFR exon 20 insertion–positive NSCLC, experts consider how patients can play a part in identifying their best treatment option.

An expert in the lung cancer and a representative from lung cancer advocacy group talk about the use of amivantamab, a novel therapy approved for treating EGFR exon 20 insertion–positive disease.

A brief discussion on the importance of accessing novel therapy and clinical trials in the setting of EGFR exon 20 insertion–positive NSCLC.

Shared insight on how molecular profiling can impact the management of EGFR exon 20 insertion–positive NSCLC and how patient advocacy groups can help patients to interpret test results.

Experts explain the presence and role of EGFR exon 20 insertion mutations in non–small cell lung cancer and highlight the role of molecular profiling.